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Background: Metastatic triple-negative breast cancer is mostly incurable, due to lack of suitable drug targets. The insulin-like
growth factor (IGF) system could provide such a target, and IGF-1 receptor (IGF-1R)-directed agents are already available, but
seem unable to control all the complexities of the system, including crosstalk with hypoxia-inducible pathways.
Methods:Migration of triple-negative MDA-231 breast cancer cells and its modulation by IGFs, the IGF-1R inhibitor NVP-AEW541
and the IGF-2-sequestering monoclonal antibody MAB292 were assessed by the scratch wound healing and Boyden chamber
assays; the effect of topotecan (inhibiting hypoxia-inducible factor-1 (HIF-1)) under hypoxia was also evaluated. Constitutive as well
as drug-modulated levels of components of the IGF and HIF-1 pathways were evaluated by western blotting and qPCR.
Results: IGF-induced migration of MDA-231 cells was not abrogated by the IGF-1R inhibitor NVP-AEW541, whereas IGF-2
sequestration by MAB292 significantly reduced cell migration. Under hypoxia, topotecan was also effective, likely by reducing
HIF-1-induced IGF-2 release. Simultaneous targeting of IGF-1R and IGF-2 or HIF-1 completely abolished cell migration.
Conclusions: IR activation may account for the failure of NVP-AEW541 to suppress MDA-231 cell migration. Ligand-targeting
compounds, or co-inhibition of the IGF and HIF-1 systems, may prevent activation of compensatory signalling, thereby providing a
valuable addition to IGF-1R inhibitor-based therapies.
Despite major advances in early detection and treatment, breast
cancer remains the most frequently diagnosed cancer and the
leading cause of cancer death in women worldwide. Strategies
targeting the primary tumour have markedly improved in the past
decade, but systemic treatments to prevent metastasis are less
effective, and about 20%–30% of patients develop metastatic
disease (metastatic breast cancer (MBC)). Several targeted agents
have been introduced into chemotherapeutic regimens for MBC in
recent years (Beslija et al, 2009; Sa´nchez-Mun˜oz et al, 2009), and
many others are in preclinical or early clinical stages of
development, mostly in combination with cytotoxic chemotherapy
(Alvarez et al, 2010). However, once the disease metastasises to
distant areas of the body, typically to the lung, bone, liver and
central nervous system, it remains incurable, with a median
survival between 2 and 4 years, depending on the subtype
(Guarneri and Conte, 2009; Alvarez et al, 2010).
Although representing only about 15% of all diagnosed breast
cancer, the triple-negative subtype (TNBC), defined as negative for
oestrogen receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) expression, accounts
for a disproportionate share of deaths, due to aggressive tumour
behaviour, poor prognosis and lack of targeted therapies. TNBC
generally occurs in younger women and is associated with a high
risk of distant recurrence (Reis-Filho and Tutt, 2008). Thus, the as
yet unmet need of effective agents for the management of
metastatic TNBC (mTNBC) is fuelling the search for novel
therapeutic targets (Liedtke and Kiesel, 2011).
A large body of evidence indicates that the insulin/insulin-like
growth factor (IGF) pathway is strongly implicated in breast cancer
(Sachdev and Yee, 2001). The system consists of three ligands
(IGF-1, IGF-2 and insulin); their cell surface receptors IGF-1
receptor (IGF-1R), IGF-2 receptor (IGF-2R, also known as the
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mannose 6-phosphate receptor M6P/IGF-2R) and two isoforms of
the insulin receptor IR-A and IR-B, as well as hybrid IR/IGF-1Rs;
six high-affinity binding proteins (IGFBP-1 to IGFBP-6) and their
proteases (Sachdev and Yee, 2007; Pollak, 2008b). High IGF-1
plasma levels are a risk factor for breast cancer in premenopausal
women (Hankinson et al, 1998), and significantly higher serum
IGF-1 levels have been found in breast cancer patients as compared
with healthy controls (Helle, 2004; Martin and Baxter, 2011). Loss
of heterozigosity at the IGF2 gene has long been observed as a
frequent occurrence in human breast cancer samples (McCann
et al, 1996) and IGF-2 binding to IGF-1R and IR-A was found to
facilitate activation of cell survival pathways (Richardson et al,
2011). The role of the IGF system in breast cancer has best been
described in ER-positive tumours and cell lines, where it
cooperates with the ER in promoting tumour growth and
progression, while hampering the success of endocrine therapy
(Zhang et al, 2011). Interestingly, IGF-1 has also been recently
reported to promote proliferation and survival of TNBC cells
(Davison et al, 2011); in addition, a role has recently been
described for IGF signalling in tumour metastasis and invasion
(Sachdev et al, 2010; Zhang et al, 2010; Saldana et al, 2013),
increasing the appeal of the IGF system as a potential target for
novel therapies directed at the ill-fated mTNBC subtype. Mono-
clonal antibodies and kinase inhibitors targeting IGF-1R have been
the object of several clinical trials in different tumour types, but
somehow the preclinical promise has failed to translate into
therapeutic efficacy so far. This is possibly due to the redundancy
and plasticity of the IGF system, whereby IR activation can
compensate for IGF-1R disruption when this is specifically targeted
(Zhang et al, 2007), especially when IGF-2 is the main stimulus
acting on cancer cells. Most human cancers overexpress both IGF-
1R and IR, leading to the formation of hybrid IGF-1R/IRs, and
IGF-2 is a known ligand for all three receptors, displaying a far
greater affinity for IR holoreceptors and IGF-1R/IR hybrids than
IGF-1 (Pandini et al, 1999; Belfiore, 2007). The role played by IGF-
2 might be particularly relevant to therapeutic failure, as release of
this factor from tumour cells can be driven by hypoxia-inducible
factor-1 (HIF-1) as part of the adaptive response to reduced oxygen
levels. Approximately 25–40% of all invasive breast cancer samples
are hypoxic and express high levels of HIF-1a, the O2-labile HIF-1
a-subunit required for transcriptional activation (Vaupel et al,
1991; Vleugel et al, 2005). Thus, the well-known ability of HIF-1 to
promote aggressive breast cancer disease might depend, at least in
part, on the recruitment of IGF-2-dependent signalling; in
addition, IGF-2 release by HIF-1 might account for the limited
clinical success of IGF-1R-targeted agents.
The present study was aimed at investigating the role played by
IGF-2 in MDA-231 TNBC cell migration by emphasising its
interactions with non-IGF-1R receptors. To this aim, we first
verified that IGF-2-induced MDA-231 cell migration is associated
with both IGF-1R and IR activation and that blocking IGF-1R with
the selective catalytic inhibitor NVP-AEW541 (Garcı´a-Echeverrı´a
et al, 2004) was unable to suppress either cell migration or IR
phosphorylation, whereas sequestering IGF-2 with the neutralising
antibody MAB292 dramatically reduced both, and completely
abrogated them in the presence of NVP-AEW541. In addition, we
also observed that HIF-1a stabilisation reproduced, albeit on a
lesser scale, the modifications observed in the presence of
exogenous IGF-2 (i.e., increased cell migration and IGF-1R/IR
phosphorylation), which could be prevented by adding the HIF-1
inhibitor topotecan and totally abolished by the topotecan/NVP-
AEW541 combination.
Overall, our data support the hypothesis that IR activation by
IGF-2 may account for the failure of IGF-1R only-targeting agents
to suppress TNBC cell migration in vitro, suggesting that it may
also be involved in the disappointing clinical activity exhibited by
such agents. Ligand-targeting compounds, or concomitant
inhibition of the IGF system and HIF-1a, may prevent activation
of compensatory signalling through IR or hybrid IR/IGF-1R and
may provide an alternative or complementary strategy for the
management of metastatic breast cancer in general and of TNBC in
particular.
MATERIALS AND METHODS
Cell lines, reagents and drugs. Three human breast cancer cell
lines were analysed: T47D and MCF-7 (ERaþ , PRþ , HER2 ) and
MDA-231 (ERa , PR , HER2 ), obtained from the American
Type Culture Collection (ATCC, Rockville, MD, USA) through the
Tumour Microenvironment Laboratory (TML, SAIC-NCI Frederick,
MD, USA), and authenticated by morphological inspection, growth
curve analysis and short tandem repeat profiling, using the Promega
PowerPlex 1.2 system (Promega, Madison, WI, USA) and the
Applied Biosystems Genotyper 2.0 software (Applied Biosystems,
Foster City, CA, USA) for analysis of the amplicons. An additional
triple-negative cell line, MDA-468, was obtained from the same
source and used to replicate some of the experiments for
confirmation purposes. Cells were routinely cultured as monolayer
at 37 1C and 5% CO2 in RPMI (or DMEM in the case of MDA468)
medium supplemented with 5% fetal bovine serum (FBS, Euroclone,
Milan, Italy) and 1% antibiotics (penicillin/streptomycin, Sigma
Aldrich, Milan, Italy).
NVP-AEW541 was kindly provided by Novartis Pharma (Basel,
Switzerland): a DMSO stock solution (10mM) was prepared and
stored at  20 1C. MAB292, rhIGF-1 and rhIGF-2 were purchased
from R&D Systems (Minneapolis, MN, USA): stock solutions were
prepared following the manufacturer’s instructions and stored at
 20 1C. Topotecan (NSC 609699) was kindly provided by the
TML (SAIC-NCI Frederick, MD, USA). Working dilutions of all
drugs were prepared in culture media immediately before use.
Quantitative RT-PCR. To analyse the components of the IGF and
HIF systems at the transcript level, cells were seeded in dishes,
allowed to grow for 24 h under normoxia (pO2 21%) and
subsequently incubated under hypoxia (pO2 1%) for an additional
24 h. Transcription of HIF-1 target genes (IGF2, VEGFA, PDK1)
was also assessed following treatment with a subtoxic concentra-
tion of topotecan (250 nM) during the 24 h of hypoxia. Total RNA
was extracted following the manufacturer’s instructions (RNeasy
kit, Qiagen, Venlo, Netherlands) and quantitated (ND-1000,
NanoDrop, Thermo Fisher Scientific, Waltham MA, USA);
250 ng (in 10 ml) of mRNA were added to 15 ml of RT solution
(High Capacity cDNA Reverse Transcription Kit, Applied
Biosystems) and retro-transcribed following the optimised proto-
col. The cDNA thus obtained was used in a real time-PCR reaction:
2.5 ng (3.75 ml) of cDNA were added with 21.25 ml of a solution
containing 2 Master Mix (TaqMan or SYBR, Applied Bio-
systems), 3 mM reverse and forward primers (final concentration
300 nM, custom made, Integrated DNA Technologies, Coralville,
IA, USA), 20 eukaryotic 18S rRNA endogenous control
(VIC/TAMRA probe, Applied Biosystems) and H2O. The run
was performed following the protocol provided by the manufacturer,
and the results were analysed by the ABI7300 software (Applied
Biosystems). Primer sequences are reported in Supplementary
Table S1.
Immunoblot analysis. To analyse the constitutive levels of the
different components of the IGF and HIF systems, as well as the
effects of growth factors and drugs on the IR/IGF-1R signalling
pathway, cells were grown for 24 h and then treated with NVP-
AEW541 (1mM) and/or MAB292 (5mgml 1) for 24 h. Cells were
exposed to rhIGF-1 or rhIGF-2 (50 ngml 1) during the last
15min before harvesting, following 6-h starvation in serum-free
medium. The effects of hypoxia (1%) on the insulin/IGF system
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were assessed on cells grown for 24 h at 21% pO2 and shifted to
hypoxia for an additional 24 h. NVP-AEW541 (1mM), MAB292
(5 mgml 1) and Topotecan (250 nM) were added, singly or in
combination, during the 24 h of hypoxia. Cell lysates were prepared
in RIPA buffer containing protease inhibitor cocktail (Sigma
Aldrich); protein phosphatases were inhibited by adding phenyl-
methylsulfonylfluoride (1mM) and sodium orthovanadate
(Na3VO4, 1mM) to the lysis buffer. Protein concentration was
determined using assay kits based on the Bradford method (Bio-
Rad Life Science, Hercules, CA, USA), and equivalent amounts
of total cell lysates (100 mg) were added with sample buffer
2 (Laemmli, Sigma Aldrich), separated by 7% or 10% acrylamide
SDS/PAGE under denaturing conditions and transferred onto
PVDF membranes. Membranes were incubated overnight with the
following primary antibodies: anti-phospho-IGF-1Rb (Tyr1316),
anti-IGF-1Rb, anti-phospho-IRb (Tyr1361), anti-IRb, anti-phos-
pho-Akt (Ser473) and anti-Akt (all from Cell Signalling Technol-
ogy, Danvers, MA, USA); anti-IGF-2R (Abcam, Cambridge, UK);
and anti HIF-1a (Novus Biologicals, Littleton, CO, USA). An anti-
actin antibody (Sigma Aldrich) was used as a control. Membranes
were then incubated with secondary anti-rabbit or anti-mouse
antibody conjugated to horseradish peroxidase (Amersham, GE
Healthcare Bio-Sciences, Pittsburgh, PA, USA). Immunoreactive
bands were revealed by Enhanced Chemiluminescence Western
Blotting Detection reagents (Amersham and Pierce) and visualised
on Hyperfilm ECL (Amersham).
ELISA assay. The release of IGF-2 in culture media was evaluated
under normoxic and hypoxic conditions. Cells were seeded onto
six-well plates and allowed to grow for 24 h before starving and
incubation at different oxygen levels (pO2 21% or 1%). Super-
natants were collected 24 h later and stored at  80 1C or
immediately quantitated using a specific ELISA kit (Insight
Genomics, Falls Church, VA, USA), according to the manufac-
turer’s protocols.
Flow cytometry. Membrane expression of IGF-1R, IGF-2R and IR
was evaluated in all cell lines. Cells were seeded in six-well plates
and allowed to grow for 48 h; they were subsequently collected,
counted and incubated for 1 h at 4 1C with specific conjugated
antibodies (IGF-1R/PE, IGF-2R/FSC and IR/PE, R&D Systems) as
well as IgG isotype control antibodies (R&D Systems). Red (PE)
and green (FSC) fluorescence was then read using a Guava
easyCyte (EMD Millipore, Billerica, MA, USA) flow cytometer.
Background fluorescence, assessed in IgG isotype controls, was
subtracted to the corresponding samples during analysis, and the
percentage of fluorescent cells was calculated.
Scratch wound-healing assay. To evaluate the effect of the
different compounds on migration of the three cell lines, cells
were seeded at high density onto specific supports (m-dish Culture
Inserts, Idibi GmbH, Planegg/Martinsried, Germany) and allowed
to grow for 24 h. The inserts were then removed, the medium was
replaced with serum-free medium, with or without the different
compounds, and the dishes were incubated in different conditions
of oxygenation (pO2 21% or 1%). Pictures of the wound scratch
were taken at the time of removal (T0) and at regular time intervals
for a total of 48 h. The experiments were repeated twice.
Boyden chamber assay. To further assess the migration of MDA-
231 cells, we also performed the Boyden chamber assay. Boyden
chambers (Cell Biolabs Inc., San Diego, CA, USA) were pre-
incubated for 30min at 37 1C in 24-well plates containing 600 ml of
culture medium and FBS (1 : 1). Cells, previously starved for 24 h,
were added on top of the chambers, treated with growth factors
and/or drugs at different oxygen levels (pO2 21% or 1%) and
allowed to grow and migrate for 24 or 48 h. At the specified end
points, the chambers were removed from the plates, fixed and
stained in two steps (EosinþAzurA/AzurB, 2min each) and
photographed. Analysis did not involve counting the number of
migrating cells but only assessing visible differences between the
treatments. The experiments were repeated twice.
RESULTS
In vitro assessment of IGF-stimulated migration and analysis of
IGF system components in three human breast cancer cell
lines. IGF-stimulated migration of MCF-7, T47D and MDA-231
cells was assessed using the scratch wound-healing and Boyden
chamber assays. In the absence of stimulation, MCF-7 and T47D
were unable to migrate, and even the addition of exogenous rhIGF-
1 or -2 did not appreciably modify their behaviour; in contrast,
MDA-231 cells, derived from a metastatic carcinoma, intrinsically
exhibited some degree of migration, which was substantially
increased following stimulation with rhIGFs (Figure 1).
We then assessed the baseline levels of some major components of
the IGF system, in order to evaluate their potential roles in the
different migratory behaviour exhibited by the three cell lines. The
results of PCR experiments (Supplementary Figure S1) indicate that
IGF-2, IGF-1R and IGF-2R mRNAs are present in all cell lines, albeit
at different levels: surprisingly, highly invasive MDA-231 showed
lower levels of IGF-1R and higher levels of IGF-2R, as compared with
both MCF-7 and T47D. IGF-1 mRNAs were undetectable in all cell
lines and are not shown. Specific analysis of the two IR variants
confirmed the results reported in the literature (Pollak, 2012): all the
T0
Control + rhIGF-1 + rhIGF-2 Control + rhIGF-1 + rhIGF-2 Control + rhIGF-1 + rhIGF-2
MCF7 MDA-231 T47D
24 h
48 h
Figure 1. Migratory behaviour of MCF-7, MDA-231 and T47D cells under normoxic conditions (pO2 21%), as assessed by the scratch wound-
healing assay. Cells were grown in specific supports for 24 h, then the inserts were removed and the medium was replaced with serum-free
medium, with or without rhIGF-1 or rhIGF2 (50 ngml1). Pictures were taken at the time of insert removal (T0) and at regular time intervals for a
total of 48 h.
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cell lines tested expressed both the A and B variants of the receptor,
with a predominance of the former; more specifically, MDA-231 cells
were found to possess the highest levels of IR-A mRNA.
However, when considering protein levels, differences among
cell lines were somewhat less evident: secreted IGF-2 in the
extracellular medium was comparable in the three cell lines
(Supplementary Figure S2, panel a), in spite of remarkable
differences in transcript; IGF-1 expression was not investigated
further, in view of the observed absence of transcript. Membrane
expression of IGF-1R, as determined by flow cytometry, was
consistent with transcript levels, whereas expression of IGF-2R and
IR did not vary among cell lines (Supplementary Figure S2, panel b);
however, it should be emphasised that IR-A and IR-B levels could
not be determined separately, due to the lack of antibodies able to
discriminate between the two isoforms.
IGF-1R and IR activation following exposure to exogenous IGFs
was assessed by western blotting, based on the levels of receptor
phosphorylation, and is shown in Figure 2 (densitometric analyses
are reported in Supplementary Figures S3, S4 and S5). In
unstimulated cells, both receptors exhibited a minimal degree of
phosphorylation, which was markedly enhanced in response to the
addition of rhIGFs to the culture medium. More specifically, as
expected, IGF-1R was activated by both ligands in all three cell
lines tested; in MDA-231, but not in the other cell lines, IR was also
relevantly activated by rhIGF-2 and, to a lesser extent and rather
more surprisingly, rhIGF-1. Exposure to the selective IGF-1R
inhibitor NVP-AEW541 predictably abrogated IGF-1R phospho-
rylation in all cell lines but did not affect IR activation.
The selective IGF-1R inhibitor NVP-AEW541 is only partially
effective in inhibiting cell migration following exposure to
rhIGFs. As shown in Figure 3A and B, exposure to NVP-AEW541
partially abrogated the migration potential of MDA-231 cells, as
assessed by both the scratch wound healing and the Boyden
chamber migration. As expected, the inhibitor appeared to be more
effective in reducing rhIGF-1 than rhIGF-2-induced migration.
The fact that migration was not completely abolished could be
explained by the inability of NVP-AEW541 to prevent IR
activation (shown in Figure 2) and to block the related downstream
pathway, as indicated by the presence of some residual Akt
phosphorylation following exposure to rhIGF-2 in the presence of
NVP-AEW541 in MDA-231 cells, in spite of a near-complete block
of IGF-1R phosphorylation (Figure 4A; densitometric analyses are
reported in Supplementary Figure S6). Interestingly, NVP-
AEW541 ehxibited some (slight) anti-migratory effect even on
unstimulated cells, which might be explained by the presence of a
low, baseline level of constitutive IGF-1R activation, as also
suggested by the western blotting results shown in Figure 4A.
Enhancing the effects of NVP-AEW541 on cell migration
by inhibiting IGF-2 signalling with the specific monoclonal
antibody MAB292. To further demonstrate that IR activation by
rhIGF-2 accounts, at least in part, for the lack of efficacy of
NVP-AWE541 in inhibiting the migration of MDA-231 cells,
receptor–ligand interaction was antagonised using a neutralising
antibody (MAB292) that binds and sequesters IGF-2. As shown in
Figure 4A, MAB292 caused a decrease in the phosphorylation of
both IGF-1R and IR in MDA-231 cells following stimulation with
rhIGF-2; furthermore, rhIGF-2-dependent IR phosphorylation, as
well as downstream Akt phosphorylation, was totally abolished
when NVP-AEW541 and MAB292 were added simultaneously to
the culture medium. This last observation can probably be
explained by the inability of the IGF-sequestering antibody to
counteract the baseline constitutive activity of IGF-1R observed
above.
In agreement with the role played by IR in MDA-231 cell
migration in response to rhIGF-2, results obtained in the scratch
wound-healing (Figure 4B) and Boyden chamber assays
(Figure 4C) indicate that, while IGF-1R inhibition alone was
insufficient in preventing IGF-2-dependent migration, blocking
the interaction of the growth factor with both signalling receptors
using MAB292 showed some effect, which resulted in an almost
complete abrogation of the migratory capacity of MDA-231 cells
when NVP-AEW541 and MAB292 are added simultaneously.
To confirm these findings on an additional TNBC cell line, the
scratch wound-healing assay was also performed on MDA-468
cells stimulated with rhIGF-2, in the presence or absence of
MAB292, NVP-AEW541 or both; the results are shown in
Supplementary Figure S7 and were similar to those obtained in
MDA-231 cells.
HIF-1a stabilisation decreases the anti-migratory effect of
NVP-AEW541. Hypoxia has been shown to cause an increase in
endogenous IGF-2 release, owing to transcriptional activation of
the corresponding gene by HIF-1 (Feldser et al, 1999; Semenza,
2012). Thus, our study was extended to examine the mechanism of
IGF-2-dependent migration, and its response to NVP-AEW541, in
hypoxic MDA-231 cells.
In agreement with literature data, secreted IGF-2 in the
extracellular medium was significantly increased from 50.5±
11.53 to 86.0±0.95 pgml 1 (Po0.05) following hypoxic incuba-
tion. Western blotting analysis indicates that both IGF-1R and
IR were partially phosphorylated under hypoxia, even in the
absence of exogenous growth factor stimulation, and that
NVP-AEW541 decreased IGF-1R phosphorylation, while leaving
IR phosphorylation virtually unaffected; in contrast, treatment
with MAB292 reduced the phosphorylation of both receptors
(Figure 5A; densitometric analyses are reported in Supplementary
Figure S8). These observations correlate with the migratory
behaviour of hypoxic MDA-231 cells, in that migration was
almost completely blocked by MAB292, whereas NVP-AEW541
only caused partial inhibition (Figure 5B and C), similarly to what
had been observed following exposure to exogenous rhIGF-2.
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Figure 2. Effect of NVP-AEW541 (1mM for 24 h) on total and phosphorylated IGF-1R and IR levels in MCF7, MDA-231 and T47D cells, in the
absence of stimulation or after exposure to rhIGF-1 or rhIGF-2 (50 ngml 1 in serum-free medium for 15min: cells were grown in serum-free
medium for the last 6 h of treatment before exposure to IGFs). Actin levels were simultaneously assessed as an internal loading control.
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HIF-1 inhibition decreases IGF-2-dependent signalling and
enhances the effects of NVP-AEW541 on cell migration. Given
the ability of hypoxia to undermine the ability of selective IGF-1R
inhibition to impair cell migration through HIF-1-dependent IGF-2
release, we finally evaluated the efficacy of the combination of
NVP-AEW541 with HIF-1 inhibition in MDA-231 cells.
To downregulate HIF-1 activity, we used topotecan, a DNA
topoisomerase I poison that has been reported to inhibit the
translation of HIF-1a mRNA (Onnis et al, 2009). The results of
western blotting analysis confirm the effectiveness of topotecan
as a HIF-1a inhibitor: as expected, and as shown in Figures 5A
and 6A, HIF-1a protein levels were consistently decreased
following 24-h exposure to 250 nM of topotecan under hypoxia;
this topotecan concentration was chosen based on a preliminary
cytotoxicity assay, indicating that o10% of the cells were killed
by the drug under our experimental conditions. (Supplementary
Figure S9, panel a). As a further corroboration of topotecan-
induced HIF-1 inhibition, real time-PCR analysis showed that
the mRNA levels of three HIF-1-regulated genes, namely, IGF-2,
VEGFA and PDK-1, were restored to almost normoxic levels
(Supplementary Figure S9, panel b) following topotecan treat-
ment. It should be emphasised that, while topotecan alone
caused a decrease in phosphorylation of both receptors, the
topotecan/NVP-AEW541 combination achieved near-complete
abrogation (Figure 6A; densitometric analyses are reported in
Supplementary Figure S10). Accordingly, topotecan, both as a
single agent and in combination with NVP-AEW541, was able to
curtail the migration of MDA-231 cells in both assays (Figure 6B
and C). Topotecan and the topotecan/NVP-AEW541 combina-
tion were observed to exert similar effects on hypoxia-induced
migration of MDA-468 cells (Supplementary Figure S11),
suggesting that our findings might be extended to other TNBC
models.
DISCUSSION
The IGF axis and, more specifically, IGF-1R have long been
considered as attractive targets for the development of novel
anticancer therapies. Besides playing a crucial role in regulating cell
growth, proliferation and differentiation, IGF-1R and its down-
stream signalling pathways have been implicated in the develop-
ment of resistance to endocrine and targeted therapies (Gao et al,
2012; Karamouzis and Papavassiliou, 2012). In addition, a role in
tumour cell migration and metastatic potential and a direct
involvement in the metastatic cascade in breast have recently been
proposed (Zhu et al, 2011). Interestingly, IGF-dependent enhanced
cellular proliferation has been documented in TNBCs, which can
provide new targets for the so far limited therapeutic options of
this sub-type that lacks expression of other druggable targets, such
as ER or HER-2 (Davison et al, 2011).
In the present study, we have focused on the role of the IGF/
insulin axis on cell migration and on the possibility to suppress this
phenotype using NVP-AEW541, a selective IGF-1R inhibitor
(Garcı´a-Echeverrı´a et al, 2004), in MDA-231 cells, a human breast
cancer cell line derived from a mTNBC. Two other cell lines, ER-
positive MCF-7 and T47D, were also examined, but although both
were shown to express IGF-1R and IR, neither displayed a
migratory response to exogenous rhIGF-1 or rhIGF-2. Our results
indicate that, while NVP-AEW541 effectively inhibits IGF-1R
phosphorylation in response to both exogenous IGFs, only rhIGF-
1-induced migration is significantly reduced by this compound,
whereas the effect of rhIGF-2 on cell migration is remarkably
resistant to this approach. Several different drug candidates
targeting IGF-1R, including both anti-receptor antibodies and
small-molecule receptor kinase inhibitors, have shown activity in
model systems, and the former (e.g., figitumumab, ganitumumab,
Control
Control
NVP-AEW541 + rhIGF-1
+ rhIGF-1
+ rhIGF-1
+ NVP-AEW541 + rhIGF-2
+ rhIGF-2
+ rhIGF-2
+ NVP-AEW541
+ rhIGF-2
+ NVP-AEW541
T0
24 h
48 h
24 h
48 h
NVP-AEW541
+ rhIGF-1
+ NVP-AEW541
Figure 3. Effect of NVP-AEW541 (1 mM) on the IGF-induced migration of MDA-231 cells, as assessed by the scratch wound-healing and Boyden
chamber assays. (A) Cells were grown in specific supports for 24 h, then the inserts were removed and the medium was replaced with serum-free
medium containing NVP-AEW541 with or without rhIGF-1 or rhIGF2 (50 ngml 1). Pictures were taken at the time of insert removal (T0) and at
regular time intervals, up to 48h. (B) Cells, previously starved for 24 h, were added on top of pre-incubated Boyden chambers and allowed to grow
and migrate (in the presence of NVP-AEW541 with or without 50 ngml 1 of rhIGF-1 or rhIGF-2) for 24 or 48 h: the cells able to migrate in the
chamber were stained and photographed, and differences between the treatments were assessed by visual inspection.
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cixutumumab) have been the subject of intense clinical research.
Although some Phase II studies of IGF-1R-specific antibodies
showed activity with little toxicity, and there were reports of major
responses, Phase III trial reports have documented a lack of
efficacy, together with significant metabolic toxicity (chiefly
hyperglycaemia; Pollak, 2008a; Gao et al, 2012; Karamouzis and
Papavassiliou, 2012). Although systemic compensatory feedback
mechanisms may account, at least in part, for the observed failure
of agents specifically targeting IGF-1R in the clinical settings, our
data indicate that compensatory mechanisms can also operate at
the cellular level, significantly hindering the anti-migratory
effect of NVP-AEW541 in our experimental setup. Our working
hypothesis was that interaction of IGFs, especially IGF-2, with IR
(which is not targeted by NVP-AEW541) might explain the failure
of this compound to suppress breast cancer cell migration. MDA-
231 cells do, in fact, express both IR-A and IR-B, and western
blotting analysis indicates that NVP-AEW541 does not affect IGF-
2-induced IR phosphorylation, nor is it able to completely abolish
downstream signalling, as shown by residual activation of Akt.
Rather more surprisingly, we also observed some degree of IR
activation in cells stimulated with IGF-1, which was not prevented
by NVP-AEW541 exposure; however, this finding could be due to
the use of supraphysiological ligand concentrations, which might
engage a significant fraction of IRs in spite of low affinity, while
IGF-2 remains the most likely IR activator under physiological
conditions. Alternatively, supraphysiological IGF-1 concentrations
might cause indirect IR activation by increasing intracellular HIF-
1a levels, as observed in experimental models derived from
different tumour types (Stoeltzing et al, 2003; Thomas and Kim,
2009; Gariboldi et al, 2010), and this in turn would cause the
release of endogenous IGF-2. Dual IGF-1R/IR inhibition could
prevail over this signal redundancy, but the role played by IR in
cellular metabolism raises serious concerns regarding the safety of
this approach in the clinic. The existence of two IR variants, the
former of which (A) is preferentially expressed in tumours,
whereas variant B is thought to have the major role in glucose
metabolism, provides a window of opportunity for intervention
specifically directed at tumours (Buck et al, 2010); however, the
fact that the two variants only differ in the presence/absence of
exon 11 (coding for a fragment of 12 aa in the C-terminal portion
of the a subunit of the receptor) makes the design of variant-
selective inhibitors and antibodies particularly challenging.
In order to simultaneously inhibit activation of both IGF-1R
and IR by IGF-2, a different and probably more feasible strategy
would be to block IGF-2 itself. IGF-2 has been reported to
selectively activate IR-A in several tumour tissues, whereas its
binding affinity for IR-B is negligible (Frasca et al, 1999; Pollak,
2012). Thus, sequestering IGF-2 would abrogate signalling through
both IGF-1R and IR-A, as well as through their hybrid isoforms, all
of which are frequently overexpressed in cancer cells, while sparing
insulin-dependent signalling through IR-B, thereby reducing the
risk of metabolic side-effects. MEDI-573 is the only antibody
currently in clinical testing that exerts its effects by neutralising not
only IGF-2 but also IGF-1, thus inhibiting IGF signalling through
IGF-1R, IR and their hybrid receptors. The ongoing Phase I clinical
trial has shown promising results and strongly suggests that MEDI-
573 might achieve this result without inducing hyperglycaemia
(Gao et al, 2011). If confirmed, this observation would be
consistent with better expectations of ligand- vs receptor-based
targeting of the IGF axis. Our data obtained with a neutralising
antibody specific for IGF-2 (MAB292) seem to support the
involvement of IGF-2-induced IGF-1R/IR activation in the poor
anti-migratory effect of NVP-AEW541. In MDA-231 cells
exposed to IGF-2, MAB292 was able to prevent phosphorylation
of both receptors; more significantly, stimulation of cell
migration by rhIGF-2 was dramatically reduced by MAB292 and
completely abolished when the antibody was combined with NVP-
AEW541.
IGF-2 neutralisation could be a particularly winning strategy,
especially considering the fact that, at low oxygen levels that are
frequently encountered within the tumour mass (pO2o2.5%),
HIF-1a stabilisation and subsequent dimerisation with HIF-1b
leads to increased IGF-2 levels, as reported in the literature (Feldser
et al, 1999; Semenza, 2012) and as observed both at the transcript
and protein levels in the present experiments on MDA-231 cells.
rhIGF-2A
B
C
Control
T0
24 h
48 h
+ rhIGF-2
+ rhIGF-2
+ MAB292
+ rhIGF-2
+ NVP-AEW541
+ MAB292
–
–
–
–
+ +
+
+
+
+
+
+– –
–MAB292
NVP-AEW541
plGF-1R (Tyr1316)
lGF-1R
pIR (Tyr1361)
pAkt (Ser473)
Akt
Actin
IR
24 h
48 h
Control + rhIGF-2
+ rhIGF2
+ MAB292
+ rhIGF-2
+ NVP-AEW541
+ MAB292
Figure 4. Inhibition of IGF-2 signalling by the specific monoclonal
antibody MAB292 enhances the anti-migratory effect of NVP-
AEW541. (A) Comparative effects of MAB292 (5mgml 1 for 24 h) and
NVP-AEW541 (1 mM for 24 h) on IGF-1R, IR and Akt phosphorylation
in rhIGF-2-stimulated MDA-231 cells (50 ngml 1 in serum-free
medium for 15min, following 6 h of starvation). Actin levels were
simultaneously assessed as an internal control. (B and C) Comparative
effects of MAB292 (5 mgml 1) and NVP-AEW541 (1mM) on rhIGF-2-
induced migration of MDA-231 cells as assessed by the scratch wound-
healing (B) and Boyden chamber (C) assays. The experiments were
performed according to the same protocol as in Figure 3A and B.
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This HIF-1-dependent increase in IGF-2 release possibly explains
why NVP-AEW541 fails to block MDA-231 cell migration,
similarly to what has been observed in the presence of exogenous
IGF-2 (although obviously to a lesser extent, considering the lower
concentration of IGF-2 released under hypoxia as compared with
the one administered exogenously). In support of the key role
played by IGF-2 in obstructing the anti-migratory effect of NVP-
AEW541 following HIF-1a stabilisation, addition of MAB292 is as
effective in inhibiting the migration of hypoxic MDA-231 cells as it
is following exposure to exogenous rhIGF-2.
Based on this observation, we suggest that a novel strategy to
overcome IR stimulation by IGF-2 following IGF-1R inhibition
may be simultaneous HIF-1a inhibition. The discovery of HIF-1
(and later HIF-2) and its role in cancer cell proliferation and
survival in conditions of reduced oxygenation (pO2o2.5%) has led
to a great interest in the development of HIF-1a and HIF-2a
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Figure 5. HIF-1a stabilisation decreases the anti-migratory effect of NVP-AEW541. (A) Effect of HIF-1a stabilisation under hypoxic conditions (pO2
1%) on total and phosphorylated IGF-1R and IR levels in MDA-231 cells, and effect of MAB292 (5mgml 1 for 24 h) and NVP-AEW541 (1 mM for
24 h) on IGF-R1 and IR phosphorylation. Cells were grown for 24 h under normoxic conditions (pO2 21%) and subsequently incubated under
hypoxia for 24 h, with or without MAB292 or NVP-AEW541. Normoxic controls were also included for comparison; actin levels were simultaneously
assessed as an internal loading control. (B and C) Comparative effects of MAB292 (5mgml 1) and NVP-AEW541 (1 mM) in inhibiting the migration
of unstimulated MDA231 cells, as assessed by the scratch wound-healing (B) and Boyden chamber (C) assays. Hypoxia was started at T0 following
24-h incubation under normoxic conditions; the experiments were performed according to the same protocol as in Figure 3A and B.
N
–
–
–
– –
+ +
+
HA B C
Control
T0
Topotecan
Topotecan
+ NVP-AEW541
24 h
48 h
Control + Topotecan
+ Topotecan
+ NVP-AEW541
24 h
48 h
TPT
NVP-AEW541
pIGF-1R (Tyr1316)
pIR (Tyr1361)
IR
HIF-1
Actin
IGF-1R
Figure 6. HIF-1 inhibition decreases IGF-2-dependent signalling and enhances the anti-migratory effect of NVP-AEW541. (A) Effect of topotecan
(TPT; 250 nM for 24 h) on HIF-1a levels and on total and phosphorylated IGF-1R and IR in MDA-231 cells under hypoxic conditions (pO2 1%), alone
or in combination with NVP-AEW541 (1 mM for 24 h), as assessed by western blotting. Cells were grown for 24 h under normoxic conditions
(pO2 21%) and subsequently incubated under hypoxia for 24 h, with or without TPT±NVP-AEW541. Normoxic controls were also included for
comparison; actin levels were simultaneously assessed as an internal loading control. (B and C) Effect of TPT (250nM), alone or in combination with
NVP-AEW541 (1 mM), on the migration of unstimulated MDA-231 cells, as assessed by the scratch wound-healing (B) and Boyden chamber
(C) assays. Hypoxia was started at T0, following 24-h incubation under normoxic conditions; the experiments were performed according to
the same protocol as in Figure 3A and B.
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inhibitors. At present, the major problem in targeting HIFs is the
lack of specific inhibitors: many chemotherapeutic drugs, in fact,
have a complete or partial inhibitory activity on HIF-1a, but this is
often accompanied by a number of off-target effects. Specific
inhibitors of HIF-1a and/or HIF-2a are currently under validation
(Onnis et al, 2009; Xia et al, 2012).
In our study, HIF-1a inhibition was achieved using topotecan, a
topoisomerase I poison with major clinical applications in the
management of ovarian and small cell lung cancer. Topotecan
inhibits HIF-1a translation through a topoisomerase I-dependent
but DNA damage-independent mechanism, suggesting that HIF-1a
inhibition could be mechanistically distinct from cytotoxicity (Onnis
et al, 2009). In our experiments, topotecan (used at subtoxic
concentrations, so that HIF-1a inhibition could predominate over
the cytotoxic effect of the drug) was confirmed to decrease HIF-1a
protein levels, as well as the expression of different HIF-1 target
genes (IGF2, VEGFA and PDK1). As a result of the decrease in IGF-2
release, phosphorylation of both IR and IGF-1R was reduced by
topotecan treatment and nearly abrogated by concurrent treatment
with topotecan and NVP-AEW541; importantly, the effect of
NVP-AEW541 on migration of MDA-231 cells under hypoxia was
restored to normoxic levels (or lower). Overall, we can conclude
that combined inhibition of IGF-1R and HIF-1 appears to result in
a synergistic effect on the migration of triple-negative MDA-231
breast cancer cells, and similar results obtained in MDA-468 cells,
also triple-negative, raise the hope that our findings may be
extended to this hard-to-treat breast cancer subtype. Thus,
inhibiting the IGF and HIF systems during the early stages of
breast cancer might provide a promising therapeutic option, most
notably for TNBC, by preventing progression to MBC, besides
reducing the contribution of these systems to the development of
resistance against both cytotoxic and targeted agents.
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